NCT02653989View on ClinicalTrials.gov

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

August 31, 2018

Conditions
Lymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma
Interventions
BIOLOGICAL

MDV9300

MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.

Trial Locations (1)

37203

Nashville

Sponsors

Lead Sponsor

Medivation, Inc.
All Listed Sponsors
lead

Medivation, Inc.

INDUSTRY

NCT02653989 - Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter